黑色素靶向[18F]-PFPN PET显像用于黑色素瘤患者预后评估
本研究回顾性分析76例黑色素瘤患者,比较[18F]-PFPN与[18F]-FDG PET的预后价值。结果示[18F]-PFPN PET参数在预测死亡和疾病进展方面优于[18F]-FDG PET,SUVmax是PFS和OS的独立预测因子。
要点
- [18F]-PFPN PET参数在预测死亡和疾病进展方面优于[18F]-FDG PET。
- [18F]-PFPN SUVmax、WBMTV、WBTLM较低者PFS和OS显著更好(log-rank P<0.05)。
- 多因素分析示[18F]-PFPN SUVmax是PFS和OS的独立预测因子。
核心结论
- [18F]-PFPN PET在黑色素瘤患者预后评估中有作用。
- [18F]-PFPN SUVmax较高的患者预后较差。
研究设计与样本
- 回顾性分析2021年2月至2022年7月接受[18F]-PFPN和[18F]-FDG PET的黑色素瘤患者。
- 共纳入76例患者(47例男性、29例女性;平均年龄57.99±10.72岁)。
- 记录临床特征、随访数据及[18F]-PFPN PET参数(SUVmax、WBMTV、WBTLM),行ROC、Kaplan-Meier和Cox回归分析。
- 中位随访12.0个月(范围1-22个月)。
主要发现
- 18例患者死亡,38例出现疾病进展。
- 中位OS为17.60个月(95%CI 15.89-19.31)。
- ROC分析中,[18F]-PFPN PET参数在预测死亡和疾病进展方面优于[18F]-FDG PET。
- [18F]-PFPN PET上SUVmax、WBMTV、WBTLM较低的患者PFS和OS显著更好(log-rank P<0.05)。
- 单因素分析中,远处转移、SUVmax、WBMTV、WBTLM与PFS和OS累积发生率显著相关(P<0.05)。
关键数值与推荐
- 多因素分析中,SUVmax是PFS和OS的独立预测因子。
- [18F]-PFPN PET参数(SUVmax、WBMTV、WBTLM)用于预后评估的ROC分析优于[18F]-FDG PET。
临床怎么用
- 原文结论为[18F]-PFPN PET在黑色素瘤患者预后评估中有作用,SUVmax较高的患者预后较差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Positron emission tomography (PET) using [18F]-PFPN, a melanin-targeted imaging tracer, has excellent diagnostic performance in patients with melanoma. This study aimed to investigate its value in prognostication and determine predictors of progression-free survival (PFS) and overall survival (OS). METHODS: We reviewed melanoma patients who underwent [18F]-PFPN and [18F]-FDG PET from February 2021 to July 2022. Clinical characteristics, follow-up data, and the following [18F]-PFPN PET parameters were recorded: maximum standardized uptake value (SUVmax), whole-body melanotic tumoral volume (WBMTV), and whole-body total lesion melanin (WBTLM). Receiver operating characteristic (ROC), Kaplan-Meier and Cox regression analyses were performed. RESULTS: Seventy-six patients (47 men and 29 women; mean age, 57.99 ± 10.72 years) were included for analysis. Median follow-up was 12.0 months (range: 1-22 months). Eighteen patients died and 38 experienced progression. Median OS was 17.60 months (95% confidence interval, 15.89-19.31). In the ROC analysis, [18F]-PFPN PET parameters were superior to those of [18F]-FDG PET in prognosticating death and disease progression. PFS and OS were significantly better in patients with lower SUVmax, WBMTV, and WBTLM on [18F]-PFPN PET (log-rank, P < 0.05). In the univariate analyses, distant metastasis, SUVmax, WBMTV, and WBTLM were significantly associated with cumulative incidence of PFS and OS (P < 0.05). In the multivariate analysis, SUVmax was an independent predictor of PFS and OS. CONCLUSIONS: [18F]-PFPN PET has a role in prognostication of melanoma patients. Patients with higher [18F]-PFPN SUVmax have worse prognosis. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT05645484. Registered 9 December, 2022, https://clinicaltrials.gov/ct2/show/NCT05645484?cond=The+Prognostic+Value+of+18F-PFPN+PET+Imaging+in+Patients+With+Malignant+Melanoma&draw=2&rank=1.
引用
- Zhang X, Lin Z, Li M, et al. Melanin-targeted [18F]-PFPN PET imaging for prognosticating patients with melanoma. Eur J Nucl Med Mol Imaging. 2023. PMID: 37191681. doi:10.1007/s00259-023-06258-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。